Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.8 USD | -0.87% | +3.94% | +4.55% |
Financials (USD)
Sales 2024 * | 2.21B | Sales 2025 * | 2.52B | Capitalization | 13.98B |
---|---|---|---|---|---|
Net income 2024 * | 490M | Net income 2025 * | 666M | EV / Sales 2024 * | 5.37 x |
Net cash position 2024 * | 2.09B | Net cash position 2025 * | 2.88B | EV / Sales 2025 * | 4.4 x |
P/E ratio 2024 * |
29.5
x | P/E ratio 2025 * |
21.8
x | Employees | 1,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -0.80% | ||
1 week | +4.31% | ||
Current month | +0.76% | ||
1 month | -1.74% | ||
3 months | -0.81% | ||
6 months | +27.20% | ||
Current year | +5.47% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 215 M€ | +11.68% | - | |
3.81% | 1 M€ | 0.00% | - | |
1.85% | 8 M€ | -.--% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 137.8 | -0.87% | 706,042 |
24-04-24 | 139 | -0.80% | 927,988 |
24-04-23 | 140.1 | +4.81% | 1,607,818 |
24-04-22 | 133.7 | +1.26% | 575,067 |
24-04-19 | 132 | -0.41% | 556,303 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.47% | 13.98B | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.86% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+28.85% | 11.66B | |
-24.93% | 8.22B |
- Stock Market
- Equities
- NBIX Stock